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A B S T R A C T
Objective: To determine the frequency of mutations known to cause autosomal
dominant Parkinson disease (PD) in a series with more than 10% of Sweden's estimated number of PD patients.
Methods: The Swedish Parkinson Disease Genetics Network was formed as a national multicenter consortium of clinical researchers who together have access to DNA
from a total of 2,206 PD patients; 85.4% were from population-based studies. Samples were analyzed centrally for known pathogenic mutations in SNCA (dupli-
cations/triplications, p.Ala30Pro, p.Ala53Thr) and LRRK2 (p.Asn1437His, p.Arg1441His, p.Tyr1699Cys, p.Gly2019Ser, p.Ile2020Thr). We compared the frequency
of these mutations in Swedish patients with published PD series and the gnomAD database.
Results: A family history of PD in first- and/or second-degree relatives was reported by 21.6% of participants. Twelve patients (0.54%) carried LRRK2 p.(Gly2019Ser)
mutations, one patient (0.045%) an SNCA duplication. The frequency of LRRK2 p.(Gly2019Ser) carriers was 0.11% in a matched Swedish control cohort and a similar
0.098% in total gnomAD, but there was a marked difference between ethnicities in gnomAD, with 42-fold higher frequency among Ashkenazi Jews than all others
combined.
Conclusions: In relative terms, the LRRK2 p.(Gly2019Ser) variant is the most frequent mutation among Swedish or international PD patients, and in gnomAD. SNCA
duplications were the second most common of the mutations examined. In absolute terms, however, these known pathogenic variants in dominant PD genes are
generally very rare and can only explain a minute fraction of familial aggregation of PD. Additional genetic and environmental mechanisms may explain the frequent
co-occurrence of PD in close relatives.
1. Introduction
Heterozygous sequence alterations in LRRK2, as well as sequence or
copy number variants (CNV) in SNCA, cause monogenic Parkinson's
disease (PD) with autosomal dominant inheritance [1,2]. LRRK2 p.
(Gly2019Ser) is considered the most common mutation that markedly
increases PD risk in carriers [3–5]. Large variation in the frequency of
LRRK2 p.(Gly2019Ser) in PD patients has been reported from different
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studies and different populations, ranging from 0% to above 40% [6].
In Sweden, only a small number of patients have been identified with
this mutation in clinical practice and in research studies [7]. SNCA
duplications or triplications have been found in more than 50 families
world-wide [8]. Other established causes of autosomal dominant PD are
exceptionally rare and most have only been reported from a few fa-
milies world-wide [9,10]. This contrasts markedly with a consistently
large proportion of at least 10–15% of PD patients reporting positive
family history for PD.
Despite many years of research on the monogenic causes of PD in-
ternationally, there are few published reports on systematic screening
of larger, population-based sample collections for pathogenic variants
in more than one gene. Thus, the overall burden of these mutations in
PD patients is hard to estimate, and it is difficult to appreciate the re-
lative frequency of various known causes of autosomal dominant PD.
We aimed at establishing the frequency of known pathogenic mutations
in both LRRK2 and SNCA, including SNCA CNVs, in a large, re-
presentative proportion of Swedish PD patients, and compare this with
the proportion of patients with familial aggregation of PD. Further, we
reviewed previous studies reporting systematic screening of PD case
series for variants in more than one dominant PD gene, and retrieved
information on the frequency of these mutations from a large genetic
database.
2. Methods
All major clinical research centers in Sweden were contacted and
those who had access to DNA from PD patients were invited to parti-
cipate in this collaborative multicenter study. All study participants had
been enrolled and provided written informed consent to their partici-
pation in the respective contributing centers’ research programs, with
ethical approval from the regional ethical review boards. Analysis of
GBA variants in a subset of 1,625 cases from these collections has
previously been reported [11].
Swedish population data was retrieved from the population data-
base at Statistics Sweden (https://www.scb.se/en/finding-statistics/
statistics-by-subject-area/population/).
Samples were transferred to one site, Lund, and genetic analyses
were performed at the Department of Clinical Genetics, Regional and
University Laboratories, Lund (E.L.-A., E.M., J.K., M.So.), and/or at the
Translational Neurogenetics Unit, Lund University (I.J-F., R.M., M.Sw.).
Seven point mutations in SNCA (NM_000345.3) and LRRK2
(NM_198,578.3) were analyzed with validated TaqMan SNP
Genotyping Assays (Life Technologies Europe): SNCA c.88G > C p.
(Ala30Pro), rs104893878; c.157G > A p.(Ala53Thr), rs104893877;
LRRK2 c.4309A > C p.(Asn1437His), rs74163686; c.4322G > A p.
(Arg1441His), rs34995376; c.5096A > G p.(Tyr1699Cys),
rs35801418; c.6055G > A p.(Gly2019Ser), rs34637584; and
c.6059T > C p.(Ile2020Thr), rs35870237 (Supplementary Table 1).
Positive control samples were available for SNCA c.157G > A [12], for
LRRK2 c.4309A > C as provided by M.T., and for LRRK2 c.6055G >
A by A.C.B [7]. PCR amplification (Supplementary Table 2) was per-
formed on Veriti Thermal Cycler with post-read performed on a 7500
Fast Real-Time PCR system (Applied Biosystems) or a CFX96 system
(CFX96tm Real-Time System, Bio-Rad Laboratories, USA). Data was
analyzed using TaqManGenotyper Software. Duplicates of samples were
analyzed in each cohort. Twenty-seven samples that were tentatively
positive in the TaqMan assays were analyzed by Sanger sequencing
(Eurofins Genomics GmbH, Germany).
Analysis of SNCA CNV was performed by two different methods.
The majority (1,556) of samples were analyzed by digital droplet PCR,
using predesigned PrimePCR ddPCR CNV Assays (Bio-Rad
Laboratories). An additional 685 samples, plus 24 that were tentatively
positive in digital PCR, were tested with TaqMan CNV analysis, using
real-time polymerase chain reaction and unquenching of fluorescent
probes for SNCA (TaqMan Copy Number Assay ID: Hs03506784_cn) and
the ribonuclease P RNA component H1 gene RPPH1 (TaqMan assay no.
4403326) as reference. Each sample was run in quadruplicates on an
Applied Biosystems real-time PCR system and analyzed using
CopyCaller software. Some samples were analyzed repeatedly and/or
with both methods. DNA from known carriers of heterozygous SNCA
duplication from the Swedish Lister Family [13,14] was used as positive
controls, and no template controls were used in all assays. Eight sam-
ples showing a tentative SNCA copy number anomaly with either
ddPCR and/or TaqMan analysis were tested with a Multiple Ligation
Probe Amplification assay according to the protocol (MDP version-006)
issued by the manufacturer (MLPA, kit P051, MRC Holland, The
Netherlands) [15].
Clinical data was extracted from medical records, self-reported by
patients during study interviews or in questionnaires, and/or obtained
through neurological examination and study visits by a movement
disorder specialist, neurologist, and/or study nurse (Table 1). This was
partially complemented with data from the Swedish Parkinson Register
(http://neuroreg.se/en.html/parkinsons-disease).
LRRK2 c.6055G > A p.(Gly2019Ser) was tested with the Global
Screening Array-24v2 (Illumina) in 942 population-based controls
without PD diagnosis, matched by age, sex and area of residence with
PD patients in MPBC cohort.
We searched PubMed for publications reporting genetic analyses of
more than one dominant PD gene in the same series of PD patients and
accessed The Genome Aggregation Database (gnomAD, http://gnomad.
broadinstitute.org/) for allele frequencies of known pathogenic muta-
tions in dominant PD genes [10,16].
3. Results
This study included a total of 2,206 PD patients from 7 Swedish
sample collections at tertiary medical centers in Lund, Umeå,
Stockholm, and Gothenburg, reflecting wide geographical distribution
(Fig. 1). The majority of patients (85.4%) were recruited in population-
based studies where all individuals diagnosed with PD in a certain
geographical area were identified from the public health services’ di-
agnosis registers and invited to participate (Table 1). Positive family
history was defined slightly differently in the studies, but 12.1% of
patients for whom such data was available reported a first-degree re-
lative with PD, and an additional 9.5% a second-degree relative with
PD (Table 1). Possible inclusion of the same individual in two studies
was controlled by comparison of unique identifiers whenever possible.
Samples were collected in the contributing studies between 1997 and
2017 (Table 1). In 2010, Sweden had a population of 9,415,570 in-
habitants. Of these, 3,507,563 were aged 50 years or older, and among
those, 81.9% were born in Sweden to parents born in Sweden, 14.6%
were born abroad or had both parents born abroad, and 3.5% had one
parent born abroad and one in Sweden.
In the 2,206 DNA samples, the call rate was 98.1% for LRRK2 and
SNCA point mutations and 98.8% for SNCA CNVs. MLPA analyses
confirmed an SNCA duplication in one of eight samples with tentatively
positive results from both digital PCR and TaqMan.
Known pathogenic point mutations were identified in 12 patients
(Table 2), and were exclusively LRRK2 p.(Gly2019Ser). This mutation
was identified in patients from three different sample collections, cor-
responding to 0.54% of all patients included. Four of these mutation
carriers had previously been reported [7] and were confirmed by both
TaqMan and Sanger sequencing. Five of the 13 detected mutation
carriers had a positive family history for PD. All mutation carriers were
of Swedish origin. LRRK2 p.(Gly2019Ser) was detected in 1 of 942
(0.11%) population-based controls from southern Sweden matched to
the MPBC. The mutation carrier was of Swedish origin, as were 85.8%
of the entire control cohort.
We identified 6 studies from 5 continents where series of PD pa-
tients were examined for mutations in more than one dominant PD gene
[17–22] and these reported a frequency of LRRK2 p.(Gly2019Ser)
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between 0 and 4.3% (Supplementary Table 3).
Data from the gnomAD database was extracted for known patho-
genic variants. There was information on 245,858 to 277,174 alleles for
identified variants, with an allele frequency of 0.049% for LRRK2 p.
(Gly2019Ser), corresponding to a carrier frequency of 0.098%. Between
populations, there were marked differences in the carrier frequency of
this variant. By far the highest carrier frequency of LRRK2 p.
(Gly2019Ser), 1.63%, was observed among Ashkenazi Jewish popula-
tion genotypes in gnomAD. This was 42 times higher than in genotypes
from all other populations in gnomAD combined (0.039%). Carrier
frequencies for all point mutations with well-established pathogenicity
in all dominant PD genes taken together was 0.11% (Supplementary
Table 4).
4. Discussion
Genetic screening of 2,206 Swedish PD patients for 8 mutations
known to cause dominant PD identified mutations in only 13 (0.59%)
individuals, while 21.6% of the patients had at least one first- or
second-degree relative with PD. Of the 13 mutations, 12 were LRRK2 p.
(Gly2019Ser) and 1 was an SNCA duplication. LRRK2 p.(Gly2019Ser) is
known to have a markedly incomplete and varying penetrance [4,5]
and was also found in 0.11% of population-based controls from one of
our genotyped cohorts. LRRK2 p.(Gly2019Ser) also represented the vast
majority (90.4%) of known pathogenic mutations in the gnomAD da-
tasets. Thus, LRRK2 p.(Gly2019Ser) is the relatively most common, but
the presently known mutations in dominant PD genes can only explain
a minute fraction of PD in the population, and similarly only a small
proportion of the familial aggregation of PD.
Strengths of this national multi-center study include that, based on
prevalence estimates [23], more than 10% of the expected number of
all PD patients in Sweden were examined, and that the vast majority
(85.4%) of patients were included in population-based studies at geo-
graphically dispersed sites within the country. There were no restric-
tions regarding age at onset or at diagnosis, and most patients in our
case series had late-onset PD with an average age of 60.7 years at
onset, or 64.4 years at diagnosis, further emphasizing the re-
presentative nature of our samples.
The 8 variants were selected to include established causes for
monogenic, dominantly inherited PD previously published in PD
patients from Sweden: SNCA duplications and p.(Ala53Thr), LRRK2 p.
(Asn1437His) and p.(Gly2019Ser) [7,12,13,24], or from historically
related populations in Norway, Denmark, United Kingdom, or Ger-
many: SNCA p.(Ala30Pro), LRRK2 p.(Arg1441His), p.(Tyr1699Cys) and
p.(Ile2020Thr) [25,26].
We see additional strengths of our study in the fact that these 8
mutations were analyzed in the same patient series, allowing us to
determine their overall burden in PD patients, and a high success rate of
the genetic analyses, including the technically more difficult testing of
SNCA CNVs. To our knowledge, this is the largest patient series tested
for SNCA CNVs reported to date.
Founder effects may lead to marked differences in the frequency of
variants between populations. For LRRK2 p.(Gly2019Ser), there is a
known South-to-North gradient in the European and Mediterranean
region, and somewhat higher frequencies are encountered in southern
Europe, for example 1.6% in a large case series from Italy [6,27]. The
background population from where the patients in the present study
were recruited can be very well defined based on Sweden's national
population database. The population of Sweden includes a considerable
percentage of individuals born in other countries, mostly in other
Europe countries, followed by Asia. Since PD starting before age 50 is
very unusual [28], we used population data from residents 50 years or
older as a reference. In the Swedish population aged 50 years or older,
14.6% were born abroad or had both parents born abroad and an ad-
ditional 3.5% had one parent born abroad. Information on ethnicity is
not typically collected in Swedish health services and was not collected
in most participating research studies, which may represent a limitation
of our study. However, we consider it likely that a considerable pro-
portion of patients in our series were of ethnically non-Swedish or non-
European origin.
Another limitation of our study is that not all dominant pathogenic
variants were analyzed, including the, in other populations, relatively
more common variants LRRK2 p.(Arg1441His), p.(Arg1441Cys) and
VPS35 p.(Asp620Asn). However, these had not been documented in
Sweden or neighboring countries.
We found only three previous studies that analyzed both SNCA CNV
and LRRK2 p.(Gly2019Ser) in the same patient series, allowing for di-
rect comparison of their frequency. These also showed that LRRK2 p.
(Gly2019Ser) is the most frequently encountered variant in dominant
PD genes, followed by SNCA duplications.
The low prevalence of pathogenic mutations in our multi-center
cohort when compared to some of the previous literature might indicate
a marked selection bias, a publication bias, or reflect true differences in
the presence of these mutations between populations. To address this
question, we compared our results with the frequency of these muta-
tions in the gnomAD dataset. Data included in gnomAD originate from a
large number of original new generation sequencing studies, including
studies on Alzheimer disease, migraine, and psychiatric disorders, but
not on PD or other neurological or neurodegenerative disorders. We
found that 0.11% of the individuals included in gnomAD carried one of
the 5 most common LRRK2 variants, almost exclusively LRRK2 p.
(Gly2019Ser), whereas none at all of the undoubtedly pathogenic SNCA
point mutations were found. There was a marked 42-fold difference in
the frequency of LRRK2 p.(Gly2019Ser) in gnomAD between 1.63% in
Ashkenazi Jews and 0.039% in all other ethnicities, confirming the
presence of a relatively ancient founder in Mediterranean populations.
LRRK2 p.(Gly2019Ser) is also known to be common in Northern African
populations but these are poorly represented in gnomAD.
We show that these SNCA and LRRK2 mutations are very rare
events, which may influence decisions about clinical genetic testing.
Among 2,206 patients, only 12 carried LRRK2 p.(Gly2019Ser), four of
whom belonged to the 21.6% (478 patients) reporting positive family
history. Thus, approximately 120 PD patients reporting one or more
first- or second-degree relative(s) with PD needed to be tested to
identify one LRRK2 p.(Gly2019Ser) carrier. For SNCA CNV, we tested
2,206 patients to identify one carrier (0.045%), who had positive family
Fig. 1. The Swedish Parkinson Genetics Network. Map showing the locations
and names of the seven contributing independent research studies. Figures re-
present the number of DNA samples from PD patients analyzed within this
study.
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history. All other genetic variants tested were not found, indicating they
have lower frequencies. A recent Australian study examined 137 pro-
bands from multi-incident families with 3 or more members with PD by
whole exome sequencing (WES) and identified 3 LRRK2 p.(Gly2019Ser)
and 2 VPS35 p.(Asp620Asn) carriers [21]. Thus, 27 patients from such
multi-incident families were examined by WES per one identified mu-
tation carrier. In most populations, genetic testing for dominant PD may
be indicated under specific circumstances and in individual patients,
and a positive result may become more likely with an increasing
number of affected family members.
The genetic architecture of PD is complex, and an interplay of more
than one genetic factor such as in digenic or oligogenic inheritance is
likely [29,30]. Thus, future research into the genetic etiology of (fa-
milial) PD should not be limited to single mutations or genes. A steadily
expanding number of WES datasets from PD patients may make it
possible to explore complex interactions.
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